Cadence Pharmaceuticals Investor/Analyst Day Highlights Strong Ofirmev …
Cadence Pharmaceuticals Investor/Analyst Day Highlights Strong Ofirmev …
Filed under: drug treatment news 2011
The drug was launched in early 2011, and thus far, the product has already demonstrated exceptional formulary adoption in hospitals, consistent sales growth, and climbing reorder rates; analysts expect sales of $ 49M in 2012, up from $ 11.5M in 2011. The …
Read more on Seeking Alpha
Geron Drops as Drug Failure Marks Latest Stumble
Filed under: drug treatment news 2011
… million at the end of 2011. When it announced its intentions to exit the stem cell business last year, shares fell. The stock took another huge tumble in September after it was disclosed that imetelstat failed in studies of the drug as a breast …
Read more on Minyanville.com
Small Pharma Sector Leaders Could Make A Profitable Diversified Portfolio
Filed under: drug treatment news 2011
The drug had promising phase 3 results via multiple trials for patients having type 1 and type 2 diabetes. While presenting the data for each of the trials, the only notable concern regarding the treatment was pain at the injection site which …
Read more on Seeking Alpha